Cyclosporine absorption profiles in pediatric kidney and liver transplant patients

Pediatric Nephrology

Volumn 18, Issue 12, 2003, Pages 1275-1279

  Kovarik, John M ^a   Hoyer, Peter F ^b   Ettenger, Robert ^c   Punch, Jeffrey ^d   Soergel, Marianne ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Universitästsklinik Essen ^*  (Germany)

^c MATTEL CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Cyclosporine; Immunosuppression; Kidney transplantation; Liver transplantation; Therapeutic drug monitoring

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADOLESCENT; ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG INDICATION; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; KIDNEY TRANSPLANTATION; LABORATORY TEST; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; MULTICENTER STUDY; PEDIATRIC SURGERY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REFERENCE VALUE; REGRESSION ANALYSIS;

ADOLESCENT; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE;

EID: 0346996883     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-003-1260-8     Document Type: Article

References (18)

1. Dunn S (2000) Neoral use in the pediatric transplant recipient. Transplant Proc 32 [Suppl 3A]:20S-26S
2. Cooney GF, Habucky K, Hoppu K (1997) Cyclosporine pharmacokinetics in pediatric transplant recipients. Clin Pharmacokinet 32:481-495
3. Trompeter R, Fitzpatrick M, Hutchinson C, Johnston A (2003) Longitudinal evaluation of the pharmacokinetics of cyclosporine microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 levels as a marker for absorption. Pediatr Transplant 7:282-288
4. Dunn S, Cooney G, Sommeraurer J, Lindsay C, McDiarmid S, Wong RL (1997) Pharmacokinetics of an oral solution of the microemulsion formulation of cyclosporine in maintenance pediatric liver transplant recipients. Transplantation 63:1762-1767
5. Nashan B, Cole E, Levy G, Thervet E (2002) Clinical validation studies of Neoral C2 monitoring: a review. Transplantation 73:S3-S11
6. 2). Transplantation 73:953-959
7. Toselli L, Pfeffer P, Stefoni S, Thervet E, Fornairon S, Keown P (2002) Minimal rejection and excellent graft function by Neoral C2 monitoring in renal transplantation: Interim results of MO2ART, a randomized prospective international study. Transplantation 74 [Suppl]:476-477
8. Levy G, Smith R, O'Grady C, Lilly LB, Girgrah N, Greig PD, Grant D (2002) Long term follow up of maintenance liver transplant patients converted to C2 cyclosporine using Neoral immunosuppression (abstract). Am J Transplant 2 [Suppl 3]:370
9. 2 monitoring in stable renal transplant recipients may reduce cyclosporine nephrotoxicity. Transplantation (in press)
10. Levy G, Thervet E, Lake J, Uchida K (2002) Patient management by Neoral C2 monitoring: an international consensus statement. Transplantation 73:S12-S18
11. Cole E, Midtvedt K, Johnston A, Pattison J, O'Grady C (2002) Recommendations for the implementation of Neoral C2 monitoring in clinical practice. Transplantation 73:S19-S22
12. Hoyer PF, Vester U (2001) Refining immunosuppressive protocols in pediatric renal transplant recipients. Transplant Proc 33:3587-3589
13. Dunn S, Falkenstein K, Cooney G (2001) Neoral C2 monitoring in pediatric liver transplant recipients. Transplant Proc 33:3094-3095
14. Hoyer PF, Ettenger R, Kovarik JM, Webb NAJ, Lemire J, Mentser M, Mahan J, Loirat C, Niaudet P, VanDamme-Lombaerts R, Offner G, Wehr S, Moeller V, Mayer H (2003) Everolimus in pediatric de novo renal transplant patients. Transplantation 75:2082-2085
15. VanDamme-Lombaerts R, Webb NAY, Hoyer PF, Mahan J, Lemire J, Ettenger R, McMahon L, Cambon N, Boger R, Kovarik JM (2002) Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients. Pediatr Transplant 6:147-152
16. Punch J, Dunn S, Lobritto S, Moeller VM, Riviere GJ, Kovarik JM (2002) Pharmacokinetics and tolerability of everolimus in stable pediatric liver transplant patients (abstract). Am J Transplant 2 [Suppl 3]:296
17. Brignol N, McMahon LM, Luo S, Tse FLS (2000) Highthroughput semi-automated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD001) and cyclosporin A (CsA) in whole blood. Rapid Commun Mass Spectrom 14:1965-1971
18. Kovarik JM, Kaplan B, Vitko S, McMahon L, Attinger M, Boger R, Rordorf C (2001) Longitudinal influence of everolimus on cyclosporine assessed over 6 months in two blinded de novo kidney transplant trials (abstract). Am J Transplant 1 [Suppl 1]:475